助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   np-project 的翻译结果: 查询用时:0.006秒
图标索引 在分类学科中查询
所有学科
肿瘤学
更多类别查询

图标索引 历史查询
 

np-project
相关语句
  相似匹配句对
     ,…,Np(.)
     ,…,Np(.)
短句来源
     . "NP ne?"
     两大类,“NP呢?”
短句来源
     The problem is NP-complete.
     该问题是NP-完备的.
短句来源
     As the problem is NP-complete.
     这个问题是一个NP-完全问题。
短句来源
     PROJECT
     项目动态
短句来源
查询“np-project”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
没有找到相关例句


Objective:To study the value of Strontium-89 Chloride therapy for bone cancer metastases in NSCLC(non-cellule lung cancer).Methods Strontium-89 Chloride therapy was used for bone cancer metastases in interphase of NP project or interventional therapy for NSCLC.Results The of Strontium-89 Chloride therapy for bone cancer metastases in interphase of NP project had an effective rate of 92.3%,and the other group had an effective rate of 92.3% Conclusion Strontium-89 Chloride therapy for bone cancer metastases in...

Objective:To study the value of Strontium-89 Chloride therapy for bone cancer metastases in NSCLC(non-cellule lung cancer).Methods Strontium-89 Chloride therapy was used for bone cancer metastases in interphase of NP project or interventional therapy for NSCLC.Results The of Strontium-89 Chloride therapy for bone cancer metastases in interphase of NP project had an effective rate of 92.3%,and the other group had an effective rate of 92.3% Conclusion Strontium-89 Chloride therapy for bone cancer metastases in interphase of NP project for NSCLC excells Strontium-89 Chloride therapy for cancer metastases in interphase of interventional therapy for NSCLC.

目的 :研究NSCLC多发性骨转移应用89SrCl2 治疗的临床价值。方法 :在以NP方案和介入治疗NSCLC间期应用89SrCl2 治疗多发性骨转移。结果 :NP方案进行全身性化疗配合89SrCl2 治疗多发性骨转移组的有效率为92 .3% ,而介入治疗配合89SrCl2 治疗多发性骨转移组的 72 .7%。结论 :以NP方案进行全身性化疗配合89SrCl2 治疗多发性骨转移优于介入治疗配合89SrCl2 治疗多发性骨转移

【Objective】To explore optimum biological effective dose(BED) of 3-dimensional conformal radiation therapy(3DCRT) for non-small cell lung cancer(NSCLC).【Methods】One hundred patients with peripheral NSCLC were divided randomly into three groups: the BED of group one was between 65~75Gy(median 72Gy),group two was between 76~85Gy(median 80Gy) and group three was between 86~100Gy(median 90Gy).All patients were treated with NP project chemotherapy after 3DCRT.The responses were observed and compared according to the...

【Objective】To explore optimum biological effective dose(BED) of 3-dimensional conformal radiation therapy(3DCRT) for non-small cell lung cancer(NSCLC).【Methods】One hundred patients with peripheral NSCLC were divided randomly into three groups: the BED of group one was between 65~75Gy(median 72Gy),group two was between 76~85Gy(median 80Gy) and group three was between 86~100Gy(median 90Gy).All patients were treated with NP project chemotherapy after 3DCRT.The responses were observed and compared according to the evaluation standard of the tumor objective treatment effect of WHO.The acute and chronic side effects were evaluated according to the RTOG and EORTC criterion system.The follow up duration in which examination repeated once every three months was one year after 3DCRT.【Results】All patients with NSCLC completed 3DCRT and chemotherapy.The response rates(CR+PR) for 3、6、9 and 12 months of group one were 86.67%、83.33%、63.33%、56.67%,of group two they were 88.57%、88.57%、80.00%、71.43%,of group three they were 94.30%、97.14%、97.14%、91.43%.The response rates had no significant differences for three and six months among three groups,but had significant differences for nine months between group one and group three,and also had significant differences for twelve months between group one and group three,group two and group three.The acute and chronic radiotherapy side-effects had no significant differences among three groups.Severe radiotherapy side-effects rarely appeared.【Conclusion】The radiotherapy side-effects of 3DCRT are mild for patients,but the recurrence rates increase if BED is lower.The results indicate optimum BED of 3DCRT for NSCLC should be about 90Gy.

【目的】探讨三维适形放射治疗非小细胞肺癌(NSCLC)的适宜等效生物剂量。【方法】将100例行三维适形放疗的周围型NSCLC患者随机分为A、B、C三组:A组为等效生物剂量在65~75 Gy之间,平均72Gy;B组为等效生物剂量在76~85 Gy之间,平均80 Gy;C组为等效生物剂量在86~100 Gy之间,平均90Gy。所有患者于放疗结束后应用NP方案化疗4周期。按WHO制定的肿瘤客观疗效评价标准对三组患者疗效进行观察比较;按RTOG和EORTC制定的早晚期放射损伤分级标准对早晚期放射反应进行评价。放疗结束后每3个月随访复查1次至1年。【结果】100例患者均顺利完成治疗。3、6、9、12个月复查有效率(CR+PR)A组分别为86.67%、83.33%、63.33%、56.67%;B组分别为88.57%、88.57%、80.00%、71.43%;C组分别为94.30%、97.14%、97.14%、91.43%。三组患者3、6个月有效率比较差异无显著性。9个月有效率C组与A组比较差异有显著性。12个月有效率C组与A组、B组比较均差异有显著性。早晚期放射反应三组之间比较均无明显差异,严重放射反应罕见。【结论】三维...

【目的】探讨三维适形放射治疗非小细胞肺癌(NSCLC)的适宜等效生物剂量。【方法】将100例行三维适形放疗的周围型NSCLC患者随机分为A、B、C三组:A组为等效生物剂量在65~75 Gy之间,平均72Gy;B组为等效生物剂量在76~85 Gy之间,平均80 Gy;C组为等效生物剂量在86~100 Gy之间,平均90Gy。所有患者于放疗结束后应用NP方案化疗4周期。按WHO制定的肿瘤客观疗效评价标准对三组患者疗效进行观察比较;按RTOG和EORTC制定的早晚期放射损伤分级标准对早晚期放射反应进行评价。放疗结束后每3个月随访复查1次至1年。【结果】100例患者均顺利完成治疗。3、6、9、12个月复查有效率(CR+PR)A组分别为86.67%、83.33%、63.33%、56.67%;B组分别为88.57%、88.57%、80.00%、71.43%;C组分别为94.30%、97.14%、97.14%、91.43%。三组患者3、6个月有效率比较差异无显著性。9个月有效率C组与A组比较差异有显著性。12个月有效率C组与A组、B组比较均差异有显著性。早晚期放射反应三组之间比较均无明显差异,严重放射反应罕见。【结论】三维适形放射治疗NSCLC的放射反应较轻,但是放疗剂量过低易导致局部复发率增高。提示三维适形放射治疗NSCLC的适宜等效生物剂量应在90Gy左右。

OBJECTIVE:To observe curative effect of late nonsmall-cell lung cancer(NSCLC) treated by chemotherapy combined with yanshu injection.METHODS: 87 cases with NSCLC were randomly divided into simple chemotherapy group(43 cases) and chemotherapy group combined with traditional Chinese medicine(44 cases).Clinical data of two groups had comparability.Evaluation of curative effect: control group took standard NP project but combined treatment group took NP project plus yanshu injection. Every three weeks constituted...

OBJECTIVE:To observe curative effect of late nonsmall-cell lung cancer(NSCLC) treated by chemotherapy combined with yanshu injection.METHODS: 87 cases with NSCLC were randomly divided into simple chemotherapy group(43 cases) and chemotherapy group combined with traditional Chinese medicine(44 cases).Clinical data of two groups had comparability.Evaluation of curative effect: control group took standard NP project but combined treatment group took NP project plus yanshu injection. Every three weeks constituted one treatment cycle,three cycles constituted one course of treatment.RESULTS: Of two-group patients,group of chemotherapy combined with traditional Chinese medicine surpassed simple chemotherapy group in recent curative effect,karnofsky performance status,pain-control and toxic adverse reactions.There was a great difference between two groups by statistical analysis.CONCLUSION: NP project combined with yanshu injection for the treatment of NSCLC has good tolerance and safety,recent curative effect surpasses that of simple chemotherapy group.It is indicated that chemotherapy combined with traditional Chinese medicine for the treatment of NSCLC is an effective way.

目的:观察岩舒注射液联合化疗治疗晚期非小细胞肺癌的疗效。方法:87例非小细胞肺癌的患者,随机分为单纯化疗组43例和化疗中药综合治疗组44例,两组病例的临床资料具有可比性。疗效评价:对照组采用标准NP方案,联合治疗组用以上NP方案+岩舒注射液,每3周为1个治疗周期,3个周期为1疗程。结果:两组患者中,化疗中药综合治疗组在近期疗效、卡氏评分、控制疼痛及毒副反应等方面都优于单纯化疗组,经统计学处理两组之间有显著性差异。结论:NP方案联合中药岩舒注射液治疗非小细胞肺癌具有较好的耐受性和安全性,近期疗效优于单纯化疗组,说明化疗联合中药治疗非小细胞肺癌是一条有效的治疗途径。

 

 


 
CNKI小工具
在英文学术搜索中查有关np-project的内容
在知识搜索中查有关np-project的内容
在数字搜索中查有关np-project的内容
在概念知识元中查有关np-project的内容
在学术趋势中查有关np-project的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社